You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol
|
|---|---|
| Published in |
BMC Cancer, March 2012
|
| DOI | 10.1186/1471-2407-12-99 |
| Pubmed ID | |
| Authors |
Karsten Geletneky, Johannes Huesing, Jean Rommelaere, Joerg R Schlehofer, Barbara Leuchs, Michael Dahm, Ottheinz Krebs, Magnus von Knebel Doeberitz, Bernard Huber, Jacek Hajda |
| Abstract |
The treatment of patients with malignant brain tumors remains a major oncological problem. The median survival of patients with glioblastoma multiforme (GBM), the most malignant type, is only 15 months after initial diagnosis and even less after tumor recurrence. Improvements of standard treatment including surgery and radio-chemotherapy have not lead to major improvements. Therefore, alternative therapeutics such as oncolytic viruses that specifically target and destroy cancer cells are under investigation. Preclinical data of oncolytic parvovirus H-1 (H-1PV) infection of glioma cells demonstrated strong cytotoxic and oncosuppressing effects, leading to a phase I/IIa trial of H-1PV in patients with recurrent GBM (ParvOryx01). ParvOryx01 is the first trial with a replication competent oncolytic virus in Germany. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Malaysia | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 124 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 17% |
| Student > Master | 20 | 16% |
| Student > Bachelor | 15 | 12% |
| Student > Ph. D. Student | 14 | 11% |
| Student > Doctoral Student | 8 | 6% |
| Other | 18 | 14% |
| Unknown | 30 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 18% |
| Biochemistry, Genetics and Molecular Biology | 20 | 16% |
| Agricultural and Biological Sciences | 16 | 13% |
| Immunology and Microbiology | 10 | 8% |
| Neuroscience | 5 | 4% |
| Other | 16 | 13% |
| Unknown | 36 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2023.
All research outputs
#1,608,502
of 22,663,969 outputs
Outputs from BMC Cancer
#232
of 8,242 outputs
Outputs of similar age
#9,607
of 160,638 outputs
Outputs of similar age from BMC Cancer
#4
of 60 outputs
Altmetric has tracked 22,663,969 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,242 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,638 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.